Compensated liver cirrhosis: Natural course and disease-modifying strategies

Abstract

Compensated liver cirrhosis (CLC) is defined as cirrhosis with one or more decompensating events, such as ascites, variceal haemorrhage, or hepatic encephalopathy. Patients with CLC are largely asymptomatic with preserved hepatic function. The transition from CLC to decompensated cirrhosis occurs as a result of a complex interaction between multiple predisposing and precipitating factors. The first decompensation event in CLC patients is considered a significant turning point in the progression of cirrhosis, as it signals a drastic decline in median survival rates from 10-12 years to only 1-2 years. Furthermore, early cirrhosis has the potential to regress as liver fibrosis is a dynamic condition. With the advent of effective non-invasive tools for detecting hepatic fibrosis, more and more patients with CLC are currently being recognised. This offers clinicians a unique opportunity to properly manage such patients in order to achieve cirrhosis regression or, at the very least, prevent its progression. There are numerous emerging approaches for preventing or delaying decompensation in CLC patients. A growing body of evidence indicates that treating the underlying cause can lead to cirrhosis regression, and the use of non-selective beta-blockers can prevent decompensation by lowering portal hypertension. Additionally, addressing various cofactors (such as obesity, diabetes, dyslipidaemia, and alcoholism) and precipitating factors (such as infection, viral hepatitis, and hepatotoxic drugs) that have a detrimental impact on the natural course of cirrhosis may benefit patients with CLC. However, high-quality data must be generated through well-designed and adequately powered randomised clinical trials to validate these disease-modifying techniques for CLC patients. This article discussed the natural history of CLC, risk factors for its progression, and therapeutic approaches that could alter the trajectory of CLC evolution and improve outcomes.

Keywords: Compensated cirrhosis; Compensated advanced chronic liver disease; Clinical decompensation; Cirrhosis reversal; Disease-modifying agents; Acute-on-chronic liver failure

Core Tip: Compensated liver cirrhosis might be reversible if the underlying cause is treated before the disease progresses. The median survival for these individuals is typically 10-12 years; however, after the first decompensation, it drastically drops to 1-2 years. As a result, the outcomes of such patients can be significantly improved by integrating a number of disease-modifying therapy strategies that address complex pathophysiology, risk factors, and triggering events linked with disease progression. This article discussed the natural course of compensated liver cirrhosis, risk factors for its progression, and potential therapeutic strategies to favourably influence its natural evolution and enhance outcomes.